For regulatory approval, biosimilar drugs must not have any clinically-meaningful differences compared to the approved medicines they are modeled after. To evaluate the safety, purity, and potency of biosimilars, drug developers use cutting-edge instruments to rapidly perform multiplex analyses and assess characteristics including target binding, functionality, and toxicity.

Download this infographic from Sartorius to learn about solutions to the challenges encountered when characterizing biosimilar drugs.

Sponsored by